SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who started this subject10/2/2000 4:17:56 PM
From: nigel bates   of 1022
 
Oct. 2 /PRNewswire/ -- Abgenix, Inc. (Nasdaq: ABGX - news) today announced the filing of an Investigational New Drug (IND) application to the FDA by Pfizer for a fully human monoclonal antibody product candidate for the treatment of cancer, which was generated with Abgenix's XenoMouse(TM) technology. This milestone triggers an undisclosed payment to Abgenix.
``We are pleased with the progress of our research alliance with Pfizer which has resulted in the first antibody generated under a XenoMouse technology collaboration to enter the clinic,'' said R. Scott Greer, chairman and CEO of Abgenix. ``This becomes the third XenoMouse antibody in human clinical trials, including two of our own. Through our collaborations and internal efforts, we believe the XenoMouse platform will continue to provide new and important antibody therapies for various disease indications.''
Abgenix's research alliance with Pfizer began in December 1997 to provide Pfizer a license to XenoMouse technology for the generation of fully human antibodies to Pfizer's antigen targets. As part of this arrangement, Pfizer made an equity investment in Abgenix. The research collaboration has been expanded several times to include currently up to five antibody product candidates named by Pfizer. Pfizer will be responsible for product development, manufacturing and marketing of any products developed through the collaboration. Abgenix will receive license fees, milestone payments plus royalties on product sales...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News